Search companies, pipelines, technologies, services, funding, financials, research guides, news, publications, and site pages. Separate keywords with spaces to require all of them.
Public content is searchable without signing in. Sign in to also search complete member company profiles. Personal notes, interactions, and private conversations are not included in public search.
6 company, guide, and curated content matches · plus news and online publication results
…tions Research guide ↗ Oligonucleotide Therapeutics & Delivery Follow siRNA, ASOs, splice modulation, conjugation, delivery, analytics, and manufacturing. Research questions & evidence boundaries Research guide ↗ In Vivo Cell Engineering & Gene Editing Explore in vivo CAR-T, nonviral editing deliver…
Oligonucleotide Therapeutics & Delivery 关注siRNA、ASO、剪接调控，以及偶联、递送、分析和制造。 如何区分序列、化学修饰与递送对结果的贡献？ 肝外递送证据需要核查哪些实验边界？ 从研究样品到开发阶段，应优先考虑哪些分析问题？ 不将所有RNA技术归为mRNA；分开呈现载荷、递送途径、组织、物种和开发阶段。 Oligonucleotide Therapeutics & Delivery Follow siRNA, ASOs, splice modulation, conjugation, delivery, analytics, and manufacturing. How can sequence, chem…
Oligonucleotide Therapeutics & Delivery
…tions Research guide ↗ Oligonucleotide Therapeutics & Delivery Follow siRNA, ASOs, splice modulation, conjugation, delivery, analytics, and manufacturing. Research questions & evidence boundaries Research guide ↗ In Vivo Cell Engineering & Gene Editing Explore in vivo CAR-T, nonviral editing deliver…
Silence Therapeutics develops siRNA medicines through its mRNAi GOLD platform. The name refers to RNA interference and gene silencing; it should not be classified as an mRNA-expression platform. Silence Therapeutics develops siRNA medicines through its mRNAi GOLD platform. The name refers to RNA int…
Oligonucleotide Therapeutics & Delivery
…ctober 27, 2026 update describes WVE-007 as an investigational GalNAc-siRNA and WVE-006 as an investigational RNA-editing oligonucleotide. These are distinct modalities, not mRNA products. Wave develops RNA-targeting medicines using RNA interference and RNA editing approaches. Its October 27, 2026 u…
Oligonucleotide Therapeutics & Delivery
… registrational WVE-006 RNA-editing study in AATD and ongoing WVE-007 siRNA Phase 2a work. The company also reports FDA support for its LC-MS assay in the planned WVE-006 program. Regulatory feedback and trial plans do not constitute marketing approval or comparative efficacy evidence. Wave季度更新介绍AAT…
Oligonucleotide Therapeutics & Delivery · Bioanalysis & Biomarkers
Vir Biotechnology announced that Phase 3 ECLIPSE 1 results for elebsiran plus tobevibart in chronic hepatitis delta will be presented on November 8, with an investor discussion on November 9. Elebsiran is an HBV-targeting siRNA; tobevibart is an antibody. The release announces the forthcoming readout and expanded Phase 2 presentations but does not disclose the Phase 3 numerical results.
An AAPS Open perspective surveys conjugation strategies for antisense oligonucleotides and siRNAs, including small-molecule ligands, cell-penetrating peptides, antibodies, and aptamers. The abstract contrasts clinically established GalNAc delivery with emerging approaches to extrahepatic tissues and discusses translation challenges. This is a synthesis of delivery platforms and clinical progress, rather than a new experimental or clinical efficacy study.
Wave's quarterly update describes planning for a registrational WVE-006 RNA-editing study in AATD and ongoing WVE-007 siRNA Phase 2a work. The company also reports FDA support for its LC-MS assay in the planned WVE-006 program. Regulatory feedback and trial plans do not constitute marketing approval or comparative efficacy evidence.
